{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:05Z","timestamp":1791357845957,"version":"4.3.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017957","name":"Health Commission of Guizhou Province","doi-asserted-by":"publisher","award":["gzwkj2024-330"],"award-info":[{"award-number":["gzwkj2024-330"]}],"id":[{"id":"10.13039\/100017957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clinthera.2025.12.013","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:44:16Z","timestamp":1770381856000},"page":"269-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety Assessment of Budesonide\/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases"],"prefix":"10.1016","volume":"48","author":[{"given":"Zhenyong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.12.013_bib0001","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1042\/CS20160487","article-title":"Cellular and molecular mechanisms of asthma and COPD","volume":"131","author":"Barnes","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.mcna.2023.08.007","article-title":"Management of chronic asthma in adults","volume":"108","author":"Nguyen","year":"2024","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0003","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0004","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","article-title":"Improving lung health in low-income and middle-income countries: from challenges to solutions","volume":"397","author":"Meghji","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(20)30416-1","article-title":"Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study","volume":"9","author":"O\u2019Byrne","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0006","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","article-title":"Controlled trial of budesonide-formoterol as needed for mild asthma","volume":"380","author":"Beasley","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0007","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","article-title":"Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (practical): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"394","author":"Hardy","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0009","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201808-1590LE","article-title":"Low-dose budesonide\/formoterol counteracts airway inflammation and improves lung function in chronic obstructive pulmonary disease","volume":"199","author":"Hakim","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/thorax-2022-219620","article-title":"Budesonide\/formoterol maintenance and reliever therapy versus fluticasone\/salmeterol fixed-dose treatment in patients with COPD","volume":"78","author":"Muiser","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-020-01041-z","article-title":"Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase iii SYGMA studies","volume":"44","author":"FitzGerald","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11595440-000000000-00000","article-title":"Safety and tolerability of high-dose budesonide\/formoterol via Turbuhaler\u00ae in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase iii study","volume":"32","author":"Saito","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0013","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/COPD.S192166","article-title":"Risks of budesonide\/formoterol for the treatment of stable COPD: a meta-analysis","volume":"14","author":"Tang","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/resp.12009","article-title":"Budesonide\/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide\/formoterol plus terbutaline in patients with asthma: phase iii study results","volume":"18","author":"Atienza","year":"2013","journal-title":"Respirology"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(06)69284-2","article-title":"Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study","volume":"368","author":"Rabe","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0017","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/14740338.2024.2393269","article-title":"A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data","volume":"24","author":"Zhou","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1329409","article-title":"From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis","volume":"15","author":"Cui","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0019","article-title":"Recombinant human growth hormone and brain neoplasm association: a pharmacovigilance and mendelian randomization analysis based on us FAERS, Japanese Jader, and Canadian CVARD","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12888-020-02525-z","article-title":"Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the united states: an approach using latent class analysis","volume":"20","author":"Anzai","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0021","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database","volume":"13","author":"Kato","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0024","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1186\/s12913-021-07260-z","article-title":"Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database","volume":"21","author":"Maity","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0025","first-page":"97","article-title":"Disproportionality analysis and causal inference in drug safety","volume":"39","author":"Scosyrev","year":"2025","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0026","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1574886310666150729112903","article-title":"The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review","volume":"10","author":"Dias","year":"2015","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0027","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","article-title":"The evolving role of disproportionality analysis in pharmacovigilance","volume":"23","author":"Fusaroli","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","article-title":"Application of data mining techniques in pharmacovigilance","volume":"57","author":"Wilson","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0029","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-025-14171-3","article-title":"The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70084","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for obeticholic acid","volume":"34","author":"Hai","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.70470\/SHIFAA\/2023\/007","article-title":"Epigenetic modifications as predictive biomarkers for cardiovascular disease: a longitudinal study on DNA methylation patterns and disease risk","volume":"2023","author":"Burhanuddin","year":"2023","journal-title":"SHIFAA"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0032","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0034","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s13300-024-01594-7","article-title":"Adverse events of oral glp-1 receptor agonist (semaglutide tablets): a real-world study based on FAERS from 2019 to 2023","volume":"15","author":"Xiong","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0035","article-title":"Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0036","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0037","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0038","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0108","article-title":"Inhaled steroids with and without regular formoterol for asthma: serious adverse events","volume":"9","author":"Janjua","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0039","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/cncr.34260","article-title":"Females have more adverse events from immune and targeted therapies","volume":"128","author":"O\u2019Rourke","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13293-024-00625-z","article-title":"Sex and gender differences in adverse events following influenza and COVID-19 vaccination","volume":"15","author":"Yin","year":"2024","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0042","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.3389\/fimmu.2018.02997","article-title":"Sex bias in asthma prevalence and pathogenesis","volume":"9","author":"Shah","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0043","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women encounter ADRs more often than do men","volume":"64","author":"Zopf","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0044","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","article-title":"Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001)","volume":"28","author":"Thiessard","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0046","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender differences in adverse drug reactions: analysis of spontaneous reports to a regional pharmacovigilance centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0047","first-page":"147","article-title":"Gender differences in the utilization of health care services","volume":"49","author":"Bertakis","year":"2000","journal-title":"J Fam Pract"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0048","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the national pharmacovigilance centre in the Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0049","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0277-9536(99)00390-1","article-title":"Constructions of masculinity and their influence on men\u2019s well-being: a theory of gender and health","volume":"50","author":"Courtenay","year":"2000","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1037\/0003-066X.58.1.5","article-title":"Men, masculinity, and the contexts of help seeking","volume":"58","author":"Addis","year":"2003","journal-title":"Am Psychol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0051","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09059180.00003609","article-title":"Epidemiology of COPD","volume":"18","author":"Raherison","year":"2009","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0052","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fped.2019.00256","article-title":"Asthma in children and adults-what are the differences and what can they tell us about asthma?","volume":"7","author":"Trivedi","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0053","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaci.2013.12.1033","article-title":"Outcomes of childhood asthma to the age of 50 years","volume":"133","author":"Tai","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0054","doi-asserted-by":"crossref","first-page":"2000612","DOI":"10.1183\/13993003.00612-2020","article-title":"Asthma medication use in obese and healthy weight asthma: systematic review\/meta-analysis","volume":"57","author":"Thompson","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/COPD.S173595","article-title":"Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD","volume":"14","author":"Hanania","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0056","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lpm.2019.01.008","article-title":"[Dyspnoea in asthma: diagnostic approach]","volume":"48","author":"Laveneziana","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0057","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-019-01128-9","article-title":"Dyspnea in COPD: new mechanistic insights and management implications","volume":"37","author":"O\u2019Donnell","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0058","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200666170-00006","article-title":"Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial","volume":"66","author":"Noonan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0059","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12890-016-0200-x","article-title":"A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax\u00ae compared to budesonide-formoterol Turbuhaler\u00ae in adults and adolescents with persistent asthma","volume":"16","author":"Virchow","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3585136","article-title":"Diagnosis and treatment of esophageal candidiasis: current updates","volume":"2019","author":"Mohamed","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0061","doi-asserted-by":"crossref","first-page":"10896","DOI":"10.12998\/wjcc.v10.i30.10896","article-title":"Prevalence and risk factors for candida esophagitis among human immunodeficiency virus-negative individuals","volume":"10","author":"Chen","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0062","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/j.1572-0241.2003.07626.x","article-title":"Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate","volume":"98","author":"Kanda","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0063","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/02770900902777783","article-title":"Esophageal candidiasis\u2014an adverse effect of inhaled corticosteroids therapy","volume":"46","author":"Aun","year":"2009","journal-title":"J Asthma"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0064","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2500\/aap2007.28.3046","article-title":"Esophageal candidiasis and candida colonization in asthma patients on inhaled steroids","volume":"28","author":"Mullaoglu","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40264-013-0029-7","article-title":"Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis","volume":"36","author":"van Boven","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0066","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2012.03.028","article-title":"Long-term safety and asthma control measures with a budesonide\/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial","volume":"130","author":"Brown","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0067","first-page":"2994","article-title":"Budesonide\/formoterol maintenance and reliever therapy in Chinese patients with asthma","volume":"125","author":"Lin","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0068","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0069","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaci.2010.04.021","article-title":"The role of viruses in acute exacerbations of asthma","volume":"125","author":"Jackson","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1440-1843.2010.01722.x","article-title":"Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review","volume":"15","author":"Mohan","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0071","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1165\/rcmb.2006-0199TR","article-title":"Role of viral infections in asthma and chronic obstructive pulmonary disease","volume":"35","author":"Proud","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0072","first-page":"327","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (Covi-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0073","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-018-1229-y","article-title":"Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis","volume":"47","author":"Yang","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0074","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chest.2015.12.018","article-title":"Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids","volume":"149","author":"Simpson","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0075","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/s41467-018-04574-1","article-title":"Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations","volume":"9","author":"Singanayagam","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0076","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027898","article-title":"Budesonide and formoterol reduce early innate anti-viral immune responses in vitro","volume":"6","author":"Davies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111363","article-title":"Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity","volume":"137","author":"Mehrabadi","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.550571","article-title":"The possible dual role of the ACE2 receptor in asthma and coronavirus (SARS-CoV2) infection","volume":"10","author":"Branco","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0079","doi-asserted-by":"crossref","first-page":"2002378","DOI":"10.1183\/13993003.02378-2020","article-title":"Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects","volume":"56","author":"Jacobs","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0080","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0081","doi-asserted-by":"crossref","first-page":"L158","DOI":"10.1152\/ajplung.00437.2020","article-title":"Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections","volume":"320","author":"Eapen","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0082","doi-asserted-by":"crossref","first-page":"210152","DOI":"10.1183\/16000617.0152-2021","article-title":"Asthma and COVID-19: an update","volume":"30","author":"Adir","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0083","doi-asserted-by":"crossref","first-page":"63","DOI":"10.70470\/SHIFAA\/2024\/008","article-title":"Study the bacterial resistance of antibiotic from opportunistic bacteria","volume":"2024","author":"Hussein","year":"2024","journal-title":"SHIFAA"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0084","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","article-title":"Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease","volume":"186","author":"Divo","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"Cardiovascular events in patients with COPD: TORCH study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0086","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0087","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0088","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/jcm10102061","article-title":"Venous thromboembolic disease in chronic inflammatory lung diseases: knowns and unknowns","volume":"10","author":"Keramidas","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0089","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S410954","article-title":"Prevalence, risk factor and clinical characteristics of venous thrombus embolism in patients with acute exacerbation of COPD: a prospective multicenter study","volume":"18","author":"Liu","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0091","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.13265","article-title":"The influence of corticosteroids on hemostasis in healthy subjects","volume":"14","author":"Majoor","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0092","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0093","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2016.02.010","article-title":"Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism","volume":"140","author":"Sneeboer","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0094","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2021.03.012","article-title":"Oral contraceptives and hormone replacement therapy: how strong a risk factor for venous thromboembolism?","volume":"202","author":"Skeith","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0095","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1007\/s12325-023-02590-2","article-title":"Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate-severe symptoms","volume":"40","author":"Singh","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0096","article-title":"Gender differences in cardiovascular disease","volume":"4","author":"Gao","year":"2019","journal-title":"Med Nov Technol Devices"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0097","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/clc.23662","article-title":"Gender differences in acute myocardial infarction-a nationwide German real-life analysis from 2014 to 2017","volume":"44","author":"Kuehnemund","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0098","first-page":"60","article-title":"Estrogen and cardiovascular disease","volume":"84","author":"Gersh","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0099","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12931-023-02545-9","article-title":"Comparative cardiovascular safety of LABA\/LAMA FDC versus LABA\/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework","volume":"24","author":"Chen","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00431-015-2610-9","article-title":"Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use","volume":"174","author":"Cavkaytar","year":"2015","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tem.2007.10.005","article-title":"The hypothalamic-pituitary-adrenal axis in asthmatic children","volume":"19","author":"Priftis","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41386-018-0167-9","article-title":"Sex differences in the hypothalamic-pituitary-adrenal axis\u2019 response to stress: an important role for gonadal hormones","volume":"44","author":"Heck","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0103","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2500\/aap.2022.43.220027","article-title":"Dose-dependent association between inhaled corticosteroid use and risk of obesity and metabolic syndrome in asthma","volume":"43","author":"Wangberg","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0104","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.2174\/092986707782359972","article-title":"Estrogens and glucocorticoid hormones in adipose tissue metabolism","volume":"14","author":"Mattsson","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1378\/chest.117.2.593","article-title":"Asthma and Cushing\u2019s syndrome","volume":"117","author":"Wilson","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0106","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1007\/s12094-025-03893-2","article-title":"Sex-related differences in the efficacy and toxicity of cancer treatments","volume":"27","author":"Santaballa Bertr\u00e1n","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0107","article-title":"Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events","volume":"4","author":"O\u2019Shea","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0109","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJMoa1511190","article-title":"Serious asthma events with budesonide plus formoterol vs. budesonide alone","volume":"375","author":"Peters","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in Collaboration with the World Health Organization, Ga(2)LEN and allergen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0111","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2222.2012.03965.x","article-title":"Severe asthma: future treatments","volume":"42","author":"O\u2019Byrne","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0112","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1080\/02770903.2021.1955377","article-title":"Disease burden and treatment adherence among children and adolescent patients with asthma","volume":"59","author":"Averell","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0113","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1183\/09031936.00047714","article-title":"Viral infections and asthma: an inflammatory interface?","volume":"44","author":"Oliver","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/pch\/17.5.251","article-title":"Managing the paediatric patient with an acute asthma exacerbation","volume":"17","author":"Ortiz-Alvarez","year":"2012","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/ph14040377","article-title":"Evaluation of the expression profile of irinotecan-induced diarrhea in patients with colorectal cancer","volume":"14","author":"Okunaka","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0116","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1753465816630208","article-title":"Inhaled corticosteroids and the increased risk of pneumonia: what\u2019s new? A 2015 updated review","volume":"10","author":"Iannella","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0117","article-title":"Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2517232","article-title":"Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases","author":"Kan","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0119","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12879-020-05440-6","article-title":"Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ppul.22563","article-title":"Suicidal ideation and thought disorder associated with the formoterol component of combined asthma medication","volume":"48","author":"del Rosario","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0121","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.70470\/SHIFAA\/2023\/003","article-title":"Pharmacogenomic profiling to tailor antidepressant therapy: improving treatment outcomes and reducing adverse drug reactions in major depressive disorder","volume":"2023","author":"Huang","year":"2023","journal-title":"SHIFAA"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0123","article-title":"Safety assessment of sodium zirconium cyclosilicate: a FAERS-based disproportionality analysis","volume":"20","author":"Yu","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33417","article-title":"Adverse events associated with eteplirsen: a disproportionality analysis using the 2016-2023 FAERS data","volume":"10","author":"Dai","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0126","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","volume":"2012","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0127","article-title":"Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.013_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:32:20Z","timestamp":1777397540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825004230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0149291825004230"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Assessment of Budesonide\/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}